Angioedema News and Research

RSS
Angioedema is the rapid swelling (edema) of the dermis, subcutaneous tissue, mucosa and submucosal tissues. It is very similar to urticaria, but urticaria, commonly known as hives, occurs in the upper dermis.
Reactions to HPV vaccine Gardasil rare

Reactions to HPV vaccine Gardasil rare

ViroPharma Inc. submits sBLA for Cinryze to treat acute attacks of hereditary angioedema

ViroPharma Inc. submits sBLA for Cinryze to treat acute attacks of hereditary angioedema

FDA accepts filing and grants priority review for DX-88 for hereditary angioedema

FDA accepts filing and grants priority review for DX-88 for hereditary angioedema

FDA licenses for marketing Cinryze for hereditary angioedema

FDA licenses for marketing Cinryze for hereditary angioedema

FDA approves Actonel (risedronate sodium) for postmenopausal osteoporosis

FDA approves Actonel (risedronate sodium) for postmenopausal osteoporosis

Tredaptive and Janumet recommended for approval in European Union

Tredaptive and Janumet recommended for approval in European Union

Highly promising Alzheimer's and Parkinson's research

Highly promising Alzheimer's and Parkinson's research

Strange behaviours linked to popular sleeping pill Zolpidem

Strange behaviours linked to popular sleeping pill Zolpidem

Hope on the horizon for hereditary angioedema sufferers

Hope on the horizon for hereditary angioedema sufferers

Sedative-hypnotic drugs to get stronger warning labels

Sedative-hypnotic drugs to get stronger warning labels

Ryogen licenses gene patent to Invitrogen

Ryogen licenses gene patent to Invitrogen

Ryogen licenses gene patent to OriGene Technologies

Ryogen licenses gene patent to OriGene Technologies

Ryogen licenses human aminopeptidase P gene patent

Ryogen licenses human aminopeptidase P gene patent

Bristol-Myers Squibb agrees to record securities litigation settlement with sweeping drug disclosure requirements announces Labaton Sucharow

Bristol-Myers Squibb agrees to record securities litigation settlement with sweeping drug disclosure requirements announces Labaton Sucharow

ACE inhibitors not needed for many heart disease patients

ACE inhibitors not needed for many heart disease patients

Results from study of Rituxan in rheumatoid arthritis show promise

Results from study of Rituxan in rheumatoid arthritis show promise